RPX

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
Thursday, February 22, 2024

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.

Auri Inc. Announces Acquisition of Gold Diamond Wawa Trust Inc.

Retrieved on: 
Thursday, February 1, 2024

DALLAS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Auri Inc. (OTCPK: AURI) (the Company) announces discussion with Gold Diamond Wawa Property Trust Inc. regarding acquisition/development of the company, including six (6) patented claims in McMurray Township.

Key Points: 
  • DALLAS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Auri Inc. (OTCPK: AURI) (the Company) announces discussion with Gold Diamond Wawa Property Trust Inc. regarding acquisition/development of the company, including six (6) patented claims in McMurray Township.
  • The targeted property is strategically located near Red Pine’s Wawa gold project "RPX", where recent drilling results have indicated a resource estimate of north of 3 million ounces of gold.
  • The talks with Gold Diamond Wawa Property Trust Inc. are focused on finalizing the terms of the acquisition/development and conducting thorough due diligence to ensure a mutually beneficial partnership.
  • Auri Inc. plans to own and collateralize the gold reserves, and use the added value for its AU, Auri Tokens, as a “gold” backed token.

RealPage Announces the Evolution of RealPage Exchange

Retrieved on: 
Tuesday, January 16, 2024

RealPage ®, a leading global provider of AI-enabled software platforms to the real estate industry, announced its evolution of RealPage Exchange® (RPX), its best-in-class integration marketplace.

Key Points: 
  • RealPage ®, a leading global provider of AI-enabled software platforms to the real estate industry, announced its evolution of RealPage Exchange® (RPX), its best-in-class integration marketplace.
  • RealPage continues to invest in RPX to help its customers grow their business, manage cyber security and data privacy risks and adapt to regulatory requirements.
  • Boosting API governance: Enhanced API governance processes, including a certification review of each integration to help ensure quality, scalability, stability and security.
  • With RPX, RealPage is leading the way in multifamily, delivering modernized APIs that provide game-changing levels of efficiency, responsiveness and customer-centricity.

Aggregator Arranged Video Patent Deal Brings Licensing Efficiency

Retrieved on: 
Friday, January 12, 2024

RPX and Sisvel, both aggregators, represented a group of 16 technology companies and 20 patent owners, respectively, to conclude a transaction related to video codecs.

Key Points: 
  • RPX and Sisvel, both aggregators, represented a group of 16 technology companies and 20 patent owners, respectively, to conclude a transaction related to video codecs.
  • The agreement provides participants with a license to patents in Sisvel’s Video Coding Licensing Platform, and resulted in significant transactional efficiencies.
  • All are represented by Sisvel and participate in the firm’s Video Coding Licensing Platform.
  • Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies.

Red Pine Announces C$5.0 Million “Bought Deal” Private Placement of Tranche 1 Flow-Through Shares and Tranche 2 Flow-Through Shares

Retrieved on: 
Thursday, November 16, 2023

TORONTO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) ("Red Pine" or the “Company”) is pleased to announce that it has entered into an agreement with Haywood Securities Inc. (“Haywood”), as lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters (together with Haywood, the “Underwriters”) pursuant to which the Underwriters have agreed to purchase, on a "bought deal" private placement basis, (i) 18,182,000 tranche 1 flow-through shares (the “Tranche 1 FT Shares”) of the Company at a price of C$0.22 per Tranche 1 FT Share (the “Tranche 1 FT Issue Price”), and (ii) 3,704,000 tranche 2 flow-through shares (the “Tranche 2 FT Shares” and together with the Tranche 1 FT Shares, the “Offered FT Shares”) of the Company at a price of C$0.27 per Tranche 2 FT Share (the “Tranche 2 FT Issue Price”), for gross proceeds to the Company of up to C$5,000,120 (the “Offering”).

Key Points: 
  • All Qualifying Expenditures will be renounced in favour of the subscribers of the Offered FT Shares effective December 31, 2023.
  • The Offering is being made by way of private placement in Canada.
  • The securities issued under the Offering will be subject to a hold period in Canada expiring four months and one day from the closing date of the Offering.
  • The Offering is subject to final acceptance of the TSXV.

Radiology Partners Launches AI Integration Platform with AWS HealthImaging

Retrieved on: 
Monday, November 27, 2023

Radiology Partners (RP), a leading radiology practice in the U.S. through its owned and affiliated practices, announced today the launch of its RPX AI orchestration platform on Amazon Web Services (AWS).

Key Points: 
  • Radiology Partners (RP), a leading radiology practice in the U.S. through its owned and affiliated practices, announced today the launch of its RPX AI orchestration platform on Amazon Web Services (AWS).
  • RPX AI is RP’s AI orchestration and integration platform, and it utilizes AWS HealthImaging, a HIPAA-eligible service for storing, analyzing and sharing medical images at petabyte scale.
  • “Using AWS HealthImaging, RP will offer RPX AI, a cloud-based platform for rapid deployment of AI medical imaging tools at scale, creating value for the entire healthcare ecosystem.
  • The topic: “Imaging AI on AWS HealthImaging.” In addition, visit RP’s booth ( North Hall 6909 ) to talk with representatives from RP and AWS and book a priority demonstration of RPX AI on AWS.

Synopsys Expands Its ARC Processor IP Portfolio with New RISC-V Family

Retrieved on: 
Tuesday, November 7, 2023

SUNNYVALE, Calif., Nov. 7, 2023 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS) today announced it has extended its ARC® Processor IP portfolio to include new RISC-V ARC-V™ Processor IP, enabling customers to choose from a broad range of flexible, extensible processor options that deliver optimal power-performance efficiency for their target applications. Synopsys leveraged decades of processor IP and software development toolkit experience to develop the new ARC-V Processor IP that is built on the proven microarchitecture of Synopsys' existing ARC Processors, with the added benefit of the expanding RISC-V software ecosystem.

Key Points: 
  • Proven and mature Synopsys MetaWare software development toolchain enables programmers to create highly optimized code for Synopsys ARC-V Processor IP.
  • (Nasdaq: SNPS ) today announced it has extended its ARC® Processor IP portfolio to include new RISC-V ARC-V™ Processor IP , enabling customers to choose from a broad range of flexible, extensible processor options that deliver optimal power-performance efficiency for their target applications.
  • Synopsys leveraged decades of processor IP and software development toolkit experience to develop the new ARC-V Processor IP that is built on the proven microarchitecture of Synopsys' existing ARC Processors, with the added benefit of the expanding RISC-V software ecosystem.
  • The 32-bit Synopsys ARC-V RHX real-time processor IP and 64-bit Synopsys ARC-V RPX host processor IP are scheduled to be available in the second half of 2024.

VIDEO - Red Pine Exploration: Gold Prospecting in Ontario's Rich Wawa Gold Camp CEO Clips Video

Retrieved on: 
Friday, October 20, 2023

Vancouver, British Columbia--(Newsfile Corp. - October 20, 2023) - Red Pine Exploration Inc. (TSXV: RPX) (OTCQB: RDEXF) - A dynamic junior exploration company, is making waves in Ontario's historic Wawa gold camp.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - October 20, 2023) - Red Pine Exploration Inc. (TSXV: RPX) (OTCQB: RDEXF) - A dynamic junior exploration company, is making waves in Ontario's historic Wawa gold camp.
  • The company, known for its strong focus on gold, boasts ten past producing mines on their property and holds an inferred resource of over 700,000 ounces of gold at an impressive concentration of five grams per ton.
  • Red Pine Exploration benefits from the exceptional jurisdiction of Ontario, with strategic proximity to three gold producers and their mills within 40 kilometers, backed by excellent infrastructure including the Trans-Canada Highway and an airport.
  • As interest rates continue to rise, the company anticipates a potential surge in the value of gold.

Osmow’s™ Opens at Walden Galleria

Retrieved on: 
Thursday, August 17, 2023

Walden Galleria, the city's ultimate shopping, entertainment, and dining destination, just got a whole lot tastier with the addition of the savory and exotic fare.

Key Points: 
  • Walden Galleria, the city's ultimate shopping, entertainment, and dining destination, just got a whole lot tastier with the addition of the savory and exotic fare.
  • A calling card for fun in the Buffalo-Niagara region, Walden Galleria boasts more than 200 retail stores, an international food court, an adventure center, and the popular Regal Cinemas Stadium 16 with RPX & 4DX theaters, making it the go-to spot for all things fun and flavorful.
  • Osmow's™ Walden Galleria is open seven days a week during the mall's open hours ready to serve up happiness in every bite.
  • Osmow’s Walden Galleria is open 7 days a week from 11am to 11pm.

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Monday, July 31, 2023

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.

Key Points: 
  • Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.
  • This press release features multimedia.
  • Under the terms of the agreement, Incyte will initiate and sponsor the clinical trial of INCB99280 and RP1 in patients with high risk, resectable cutaneous squamous cell carcinoma (CSCC), with the clinical trial expected to initiate in early 2024.
  • Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study.